Morgan Stanley analyst Laura Hindley lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 750 from DKK 755 and keeps an Equal Weight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma Reports Transformative Year with Strong R&D Focus
- ZLDPF Earnings this Week: How Will it Perform?
- Zealand Pharma initiated with an Equal Weight at Morgan Stanley
- Zealand Pharma downgraded to Hold from Buy at SEB Equities
- Zealand Pharma price target lowered to DKK 750 from DKK 815 at Deutsche Bank